Edition:
United States

Pluristem Therapeutics Inc (PSTI.OQ)

PSTI.OQ on NASDAQ Stock Exchange Capital Market

1.49USD
3:37pm EST
Change (% chg)

$-0.02 (-1.32%)
Prev Close
$1.51
Open
$1.50
Day's High
$1.52
Day's Low
$1.49
Volume
13,929
Avg. Vol
21,862
52-wk High
$1.85
52-wk Low
$0.74

PSTI.OQ

Chart for PSTI.OQ

About

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its... (more)

Overall

Beta: 0.18
Market Cap(Mil.): $122.34
Shares Outstanding(Mil.): 81.02
Dividend: --
Yield (%): --

Financials

  PSTI.OQ Industry Sector
P/E (TTM): -- 40.79 30.35
EPS (TTM): -0.30 -- --
ROI: -52.13 -0.56 15.27
ROE: -55.59 -1.20 16.60

BRIEF-Pluristem's pivotal phase III critical limb ischemia trial approved by UK regulatory agency

* Pluristem therapeutics inc - pluristem expects to begin patient enrollment in UK in first half of 2017

Nov 01 2016

BRIEF-Pluristem signs term sheet for $30 million equity investment agreement

* Pluristem signs term sheet for $30 million equity investment agreement with a leading institutional life sciences fund

Oct 25 2016

BRIEF-Pluristem says FDA has given positive feedback on proposed phase III trial

* Says as of June 30 had approximately $33 million in cash and cash equivalents, bank deposits, restricted deposits and marketable securities

Sep 12 2016

BRIEF-Pluristem's program awarded an $8 million grant

* Critical Limb Ischemia (CLI) program in European Union has been awarded an $8 million grant Source text for Eikon: Further company coverage:

Aug 09 2016

BRIEF-Pluristem receives positive feedback from FDA, gears up for phase III trial of PLX-PAD in critical limb ischemia

* Pluristem receives positive feedback from FDA and gears up for Phase III trial Of PLX-PAD in critical limb ischemia

Aug 02 2016

BRIEF-Pluristem advances towards late-stage trial of PLX-PAD for recovery post hip surgery

* Pluristem advances towards multinational phase III trial of PLX-PAD to improve recovery following surgery for hip fracture

Jul 27 2016

BRIEF-Pluristem advances its U.S. FDA trial in hematologic indication

* Pluristem advances its U.S. FDA trial in hematologic indication

Jul 11 2016

Earnings vs. Estimates